CollPlant announced it has signed a new, exclusive distributor agreement in Turkey to market Vergenix FG, for the treatment of chronic wounds. The one year agreement includes a two-year extension option. The market potential for the treatment of chronic wounds in Turkey is estimated at in excess of 400,000 procedures annually.
"We have received excellent feedback from opinion leaders in Europe who have been using the product, and the signing of the agreement with the Turkish distributor represents a further layer in the implementation of the Company's sales strategy on the continent. Our objective is to build up the sales infrastructure for Vergenix FG through distributors in various, key territories," Yehiel Tal, Chief Executive Officer of CollPlant said.